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BY-NC-ND license (http://creativecomBackground/Purpose: For estrogen-receptor positive breast cancer cases, tamoxifen has been
the most important adjuvant hormonal therapy for the purpose of reducing recurrence rates
and prolonging disease free survival. However, several side effects have been noticed, and fatty
liver is one of themost common side effects among them. Since fatty liver is a commonproblem in
the general population, we wanted to examine the effects of tamoxifen under pre-existing fatty
liver conditions and evaluate the prevalence of tamoxifen-related impaired liver function.
Methods: We recruited breast cancer cases at ages 2070 years and divided them into tamoxifen
or control groups. Personal information was collected, and fasting blood tests and abdominal ul-
trasound were performed. The changes of fatty liver degree between the initial and follow-up
ultrasound were divided into five categories.
Results: Of the 406 enrolled participants, 266 were in the tamoxifen group and 140 were in the
control group. The tamoxifen group had a higher risk of newly developed fatty liver [hazard ratio
(HR) Z 3.69; 95% confidence interval (CI) 1.678.13), lower rate of improved fatty liver
(HR Z 0.33; 95% CI 0.150.75), and higher rate of worsened fatty liver (HRZ 2.11; 95% CI
1.024.35).
Conclusion: The current study suggests that tamoxifen treatment is associated with the risk of
fatty liver either by increasing the risk of newly developed fatty liver conditions orworsening pre-
vious fatty liver conditions, and even retarding fatty liver improvement.
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Breast cancer has emerged as the most common female
malignancy in Taiwan since 2003. According to the statistics
of the Department of Health in Taiwan, the incidence of
breast cancer was 59.9/100,000 women in 2009.1,2
Tamoxifen was approved by the Food and Drug Adminis-
tration of the USA in 1977 as an adjuvant hormonal therapy
for estrogen-receptor-positive (ER positive) breast cancer
patients.3 As tamoxifen is inexpensive and well-tolerated,
it became the first line of adjuvant hormonal therapy. Ac-
cording to meta-analysis, consecutive 5-year tamoxifen
treatment can reduce mortality rate by 31%.4 Even though
it is well tolerated, several side effects are inevitable, and
fatty liver is one of the most common side effects among
these.
Several studies showed that taking tamoxifen may incur
a 30e40% risk of developing nonalcoholic fatty liver disease
(NAFLD), according to different diagnosis instruments.5e8
NAFLD is a common benign liver disease, its prevalence is
around 2030% in the West and 11.441% in Taiwan.9,10 In
general, fatty liver is most likely to be associated with
obesity11 and unhealthy diet habits12; yet, this seems not to
be the case in breast cancer patients in Taiwan. We noticed
most patients followed a relative healthy lifestyle after
being diagnosed with cancer, in order to prevent disease
recurrence. From the view point of public health, fatty
liver is worth early intervention as this might decrease the
risk of all-cause mortality and diabetes.13e16 Considering
that potential adverse effects may reduce compliance
when taking tamoxifen, we decided to investigate this
issue; although not wishing to raise another medical
concern during the 5-year treatment period. Previous
studies have focused on the new development of
tamoxifen-induced fatty liver and the lack of consideration
for real world conditions i.e. the high prevalence of fatty
liver in the general population. The more important
concern is related to pre-existing liver conditions; hence,
we wished to thoroughly explore the drug effect on
different pre-existing liver conditions. The aim of this study
is to assess the impact of tamoxifen-related fatty liver
among breast cancer patients and to evaluate the conse-
quent prevalence of an abnormal liver function test (LFT).
Materials and methods
Patients
This is a hospital-based retrospective cohort study, con-
ducted from April 1, 2013 to March 31, 2014 at the Breast
Clinic, Kaohsiung Veterans General Hospital, Southern
Taiwan, with the approval of the Kaohsiung Veteran Gen-
eral Hospital institutional review board (IRB). Patient re-
cords were de-identified prior to analysis. The IRB reviewed
the research proposal, and IRB approval was obtained on
March 18, 2013, IRB N0: VGHKS13-CT4-04. Under this
permission, the study was conducted from April 1, 2013.
Breast cancer cases diagnosed from January 2008 to April
2014 including patients of 20 years to 70 years of age were
eligible, and the written informed consent of each partic-
ipant was obtained for their clinical records to be used inthis study. Clinical records include both the first hospitali-
zation (initial data) for breast cancer treatment and labo-
ratory check-up data at follow-up time (later data). The
exclusion criteria were the presence of underlying viral
hepatitis, alcoholic hepatitis (70 g/wk for women),17 liver
metastasis, and chemotherapy-induced liver disease. Those
who were taking antilipid agents or steroids which may
influence fatty liver conditions were also excluded. Ac-
cording to the use of tamoxifen (consecutive usage for
more than 3 months until the enrolment date) or not, the
cases were divided into a tamoxifen group or control group.
Those who did not receive tamoxifen or those using aro-
matase inhibitors were defined as the control group. At
enrolment time, personal data were collected from a life-
style questionnaire and an 8-hour fasting day was arranged
to perform the follow-up blood tests and abdominal ultra-
sound (later ultrasound) to evaluate fatty liver condition.
Lifestyle questionnaire
All demographic data were collected via a lifestyle ques-
tionnaire. Measurement of present body height, weight,
waist, and body mass index (BMI) was calculated. The
questionnaire was used to evaluate the patient’s lifestyle
after diagnosing breast cancer, including consumption of
sweetened soft drinks (yes/no), exercise condition (yes/
no), and time given to exercise every week. Regarding ex-
ercise time, 150 min/wk was used as a cut-off point, ac-
cording to the recommendation for adults from the
American College of Sports Medicine and the American
Heart Association.18 The personal and family histories of
hypertension, diabetes, and hyperlipidemia were also
reviewed.
Abdominal ultrasound and blood test at follow-up
time
Fasting for 8 hours was required for the blood test and
abdominal ultrasound. Serum aspartate aminotransferase
(AST, normal range, 035 IU/L), alanine transaminase (ALT,
normal range, 040 IU/L), creatinine, uric acid, triglycer-
ide, total cholesterol, high-density lipoprotein (HDL), low-
density lipoprotein (LDL), sugar, hemoglobin A1c (HbA1c),
and insulin were measured. Insulin resistance (IR) was
calculated using the HOMA-IR formula [HOMA-IR Z fasting
insulin (mU/L)  fasting glucose (mmol/L)/22.5].
Pathologic diagnosis remains the gold standard for
establishing the diagnosis of fatty liver; however, it is
invasive and has a relatively high cost. Therefore, multiple
radiology modalities such as abdominal ultrasound,
computerized tomography, and magnetic resonance imag-
ing are used clinically. In this study, ultrasound was used to
diagnose fatty liver. The severity of fatty liver was graded
as normal, mild, moderate, and severe, according to the
echogenicity of the liver parenchyma.19 Ultrasound was
performed by well-trained radiation technologists and
rated by radiology specialists with consensus of grading.
The initial body weight, liver function, and abdominal ul-
trasound of the first hospitalization (initial ultrasound) for
breast cancer treatment was obtained and used as a
reference for body weight and liver function change.
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“Breast cancer disease year” was the duration from the
date of first hospitalization for breast cancer treatment to
the follow-up blood test date. “Follow-up time”, to avoid
bias and have an equal base line, we omitted the previous
treatment time, including surgery, chemotherapy, and
radiotherapy course. Therefore, the follow-up time was
calculated from the first tamoxifen prescription date in the
tamoxifen group, and the first outpatient clinic follow up in
the control group, to the follow-up blood test date.
Outcomes
The primary outcome was fatty liver changes using abdom-
inal ultrasound. To quantify the change of severity, we
turned the order scale to a numeric scale for statistical
analysis. We rated normal, mild, moderate, and severe fatty
liver as 0, 1, 2, and 3, respectively. We compared the scoring
change between initial and follow-up ultrasound to assess
the development of fatty liver. Accordingly, we obtained the
following five categories of fatty liver change: (1) fatty
improved; (2) normal and no change; (3) fatty as before; (4)
normal to fatty; and (5) worsened fatty (Figure 1). The sec-
ondary outcome was the prevalence of abnormal LFT under
different fatty liver conditions. The definition of abnormal
LFT in this study was AST 35 IU/L, or ALT 40 IU/L.
Statistical analysis
The statistical analysis was performed with STATA software
v.13.0 (StataCorp LP Texas). All data were expressed as
frequency (percentage) or mean standard deviation. We
used three models to evaluate the effect of tamoxifen
treatment on different developments for NAFLD. TheFigure 1 Flow diagram of the patient population and five catego
cancer cases were eligible in this study, 266 (64%) of the cases wereoutcomes were: a newly developed fatty liver [compared (4)
normal to fatty with (2) normal and no change]; an improved
fatty liver [compared (1) fatty improved with (3) fatty as
before]; and a worsened fatty liver [compared (5) worsened
fatty with (3) fatty as before] in the three models, respec-
tively. The duration for the time observed was the followed-
up time from the start of tamoxifen use or the first outpa-
tient clinic follow up in the control group to the examination
of NAFLD (at the same time of follow-up blood test date).
Patients with censor data were defined as those without the
outcomes at the time the NAFLD was examined. Since these
assessments were time-dependent, the Cox proportional
hazardmodels were used to evaluate the effect of tamoxifen
treatment on different developments for NAFLD adjusted for
the possible confounding variables.Results
Study patients and follow-up
From April 1, 2013 to March 31, 2014, 422 participants were
recruited: one participant was older than 70 years, nine
participants with incomplete questionnaires, five partici-
pants with hepatitis B, and one participant with hepatitis C
were all excluded; therefore, 406 participants were
enrolled (mean age 53.2  8.2 years), 306 (75.4%) ER pos-
itive, and 100 (24.6%) ER negative. Among the ER positive
participants, 266 (86.9%) received tamoxifen treatment and
were defined as the tamoxifen group. The control group
contained 140 participants, including 100 ER negative par-
ticipants and 40 ER positive participants who were not
taking tamoxifen (32 refused any drugs due to personal
reasons, eight were taking aromatase inhibitors). The mean
follow-up time was 26.7 months; patient characteristics are
summarized in Table 1. The mean weight at the time ofries of fatty liver change. This figure indicates that 406 breast
in the tamoxifen group and 140 (36%) were in the control group.
Table 1 Characteristics of 406 participants according to whether they were treated with tamoxifen or not.
Overall n Z 406 Control n Z 140 Tamoxifen n Z 266 p
Age (y) 53.2  8.2 53.8  8.3 52.9  8.1 0.260
Disease yeara (y) 2.76  1.39 2.90  1.30 2.69  1.43 0.152
Height (cm) 156.7  5.5 156.6  5.3 156.7  5.6 0.819
Weight, initiala (kg) 59.1  9.7 58.9  9.2 59.2  9.9 0.775
BMI, initialb (kg/m2) 24.1  3.9 24.1  .6 24.1  4.1 0.799
Weight, laterc (kg) 59.8  9.9 59.5  9.9 60.0  9.9 0.695
Weight change (kg) 0.75  3.8 0.68  4.2 0.79  3.6 0.770
BMI, laterb (kg/m2) 24.4  3.9 24.3  3.7 24.4  4.0 0.691
Waist (cm), laterb 81.1  9.5 81.1  9.6 81.1  9.4 0.952
Ever pregnant 342 (84.2%) 118 (84.3%) 224 (84.2%) 0.984
First pregnant age (y) 26.4  4.8 25.9  4.9 26.7  4.7 0.162
Menopause 302 (74.4%) 106 (75.7%) 196 (73.7%) 0.656
Biochemistry (initial)a
AST (IU/L) 21.0  6.8 21.2  6.4 20.9  7.0 0.696
ALT (IU/L) 22.6  14.1 23.8  13.7 22.0  14.3 0.226
Sugar, not specific (mg/dL) 111.7  36.4 110.6  39.1 112.3  35.0 0.647
Disease stage 0.068
Carcinoma in situ 48 (11.8%) 10 (7.1%) 38 (14.3%)
I 155 (38.2%) 48 (34.3%) 107 (40.2%)
II 152 (37.4%) 61 (43.6%) 91 (34.2%)
III 50 (12.3%) 21 (15.0%) 29 (10.9%)
IV 1 (0.25%) 0 1 (0.38%)
Chemotherapy 227 (55.9%) 101 (72.1%) 126 (47.4%) <0.001*
Family history
Diabetes 141 (34.7%) 45 (32.1%) 96 (36.1%) 0.427
Hypertension 208 (51.2%) 71 (50.7%) 137 (51.5%) 0.880
Hyperlipidemia 30 (7.4%) 9 (6.4%) 21 (7.9%) 0.591
Breast cancer 76 (18.7%) 32 (22.9%) 44 (16.5%) 0.121
Personal history
Diabetes 34 (8.4%) 7 (5.0%) 27 (10.2%) 0.075
Hypertension 66 (16.3%) 20 (14.3%) 46 (17.3%) 0.435
Hyperlipidemia 32 (7.9%) 10 (7.1%) 22 (8.3%) 0.689
Regular exercise 270 (66.5%) 98 (70.0%) 172 (64.7%) 0.279
Exercise (min/wk) 166.8  177.1 175.6  167.8 162.1  182.0 0.464
Night sleep (h) 6.5  1.4 6.5  1.3 6.5  1.5 0.723
Sweetened soft drink (yes/no) 52 (12.8%) 22 (15.7%) 30 (11.3%) 0.204
Alcohol (yes/no) 8 (2.0%) 3 (2.1%) 5 (1.9%) 0.856
Follow up periodd (mo) 26.7  15.5 24.8  13.6 27.7  16.3 0.078
Data are expressed as mean  SD or n (%).
*Categorical variables using Chi-square test with significant level at p < 0.05.
ALT Z alanine transaminase; AST Z aspartate aminotransferase; BMI Z body mass index.
a Disease year was the duration from the date of first hospitalization for breast cancer treatment to the follow-up blood test date.
b Data during the first hospitalization for breast cancer treatment.
c Data at the date of performing follow-up blood test.
d Follow-up period was calculated from the first tamoxifen prescription date in the tamoxifen group and the first outpatient clinic
follow-up in the control group to the follow-up blood test date.
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24.1 kg/m2; at follow-up time, the mean weight and BMI
had only slightly increased. Except for a higher chemo-
therapy rate being found among the control group (72.1%
vs. 47.4%), the baseline characteristics of both groups did
not significantly differ in terms of age, family, and personal
history of diabetes mellitus, hypertension, hyperlipidemia,
breast cancer stage, diet habits, and exercise condition.
Regarding the prevalence of fatty liver, as Figure 2 shows,
both groups had similar percentages of varying degrees offatty liver at first; nevertheless, higher moderate and severe
degrees and less normal and mild degrees of fatty liver were
found in the tamoxifen group at follow-up time. We further
discussed the five different categories of fatty liver changes,
this revealed that the tamoxifen group tended to exhibit
more prominent fatty liver changes; “(4) normal to fatty”
24.4% versus 5.0%, “(5) worsened fatty ” 21.8% versus 6.4%.
We checked the fasting blood test results at follow-up time,
and higher rates of abnormal LFT, triglyceride, and LDL were
demonstrated in the tamoxifen group (Table 2). The
Figure 2 Fatty liver distribution in 406 participants at initial
and follow-up time. This figure indicates the changes in various
degrees of fatty liver during follow-up time. More prominent
fatty liver changes in the tamoxifen treatment group were
noticed.
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degree of fatty liver, AST 35 IU/L (normal: 1.0%, mild:
12.0%, moderate: 32.6%, severe: 42.9%) and ALT  40 IU/L
(normal: 1.6%,mild: 14.0%,moderate: 35.9%, severe: 52.4%).
Of the 406 participants, the tamoxifen group had higher rates
of abnormal ASTat follow-up time compared with the control
group (16.9% vs. 5.7%, pZ 0.001) and ALT (17.3% vs. 10.7%,
pZ 0.078). Taking into account the different degrees of fatty
liver changes (Table 3), elevated liver function was more
obvious in the tamoxifen group with “worsened fatty” con-
dition. Table 4 shows the effect of tamoxifen treatment on
different condition of fatty liver disease among breast cancer
patients with adjusting age, initial BMI, diabetes, chemo-
therapy, and exercise time over 150 min/wk. In terms of
“newly developed fatty liver”, the tamoxifen group displayed
a higher risk, the adjusted HR was 3.69 (95% CI 1.678.13,
p< 0.001). For the effect of “improved fatty liver”, less rate
of improvement was found in the tamoxifen group, the
adjusted HR was 0.33 (95% CI 0.150.75, p Z 0.002). In
contrast to the control group, the tamoxifen group had a
higher risk of “worsened fatty” condition, the adjusted HR
was 2.11 (95% CI 1.024.35, p < 0.001).Table 2 Blood test results of 406 participants at follow-up time
Overall n Z 406 Contr
Biochemistry (later)
AST (IU/L) 27.8  18.0 24.4
ALT (IU/L) 26.6  23.3 23.5
Creatinine (mg/dL) 0.81  0.14 0.82
UA (mg/dL) 5.5  0.24 5.2
TG (mg/dL) 135.7  144.6 113.0
Cholesterol (mg/dL) 193.8  37.9 205.6
HDL (mg/dL) 52.0  13.0 52.6
LDL (mg/dL) 97.4  29.9 107.3
Fasting sugar (mg/dL) 99.5  19.2 100.0
HBA1C (%) 6.1  5.4 6.5
Insulin (mU/L) 8.0  8.3 8.3
HOMAR-IR 2.02  2.21 2.10
*Continuous variables using two-sample t test with significant level a
ALT Z alanine transaminase; AST Z aspartate aminotransferase; HBA
IR Z fasting insulin (mU/L)  fasting glucose (mmol/L)/22.5; LDL ZDiscussion
The most anticipated benefit of tamoxifen is improved
breast cancer survival rates based on a sufficient treatment
time; nevertheless, a 5-year long treatment course may
arouse some side effects that may influence drug compli-
ance.20 In addition, some medical consequences can be
avoided if timely intervention takes place. In our study, 40%
of participants had different degrees of fatty liver at the
initial survey; the prevalence was consistent with previous
investigations.9,10 The severity of the fatty liver was similar
in both groups initially; however, different outcomes were
noticed later when some showed improved fatty liver, while
others either remained at the same condition or worsened.
We examine the causes of these differences.
We found higher rates of fatty liver in the tamoxifen group
at follow-up time. When considering the possible causes of
fatty liver, we evaluated personal lifestyle, body weight, and
potential drugs may intervene. In the lifestyle questionnaire,
weevaluated sweetened soft drink habits, basedonexcessive
dietary fructose intake playing an important role in the cur-
rent epidemic of fatty liver,12 consumption was found not to
be as high as in the general population and there was no sig-
nificant difference in both groups (control 15.7% vs. tamox-
ifen 11.3%, pZ 0.647); in addition, 66.5% of the participants
had regular exercise, andmost of them hadmade this change
to improve their health since being diagnosed with breast
cancer. Regarding body weight, the average BMI was 24 kg/
m2, a relatively healthy weight, this finding is similar to a
study in Japan, which indicated tamoxifen-related fatty liver
was found in about one-third of nonobese breast cancer pa-
tients, and BMI Z 23.6 kg/m2 was the cut-off point.8,21
Therefore, lifestyle or body weight was less likely to be the
cause of fatty liver in our study. As we know, the most
effective way to improve fatty liver is to control body weight
and exercise regularly. Because 40% of the participants had
different degrees of fatty liver initially, they should benefit
from a healthy lifestyle; however, such kind of lifestyle
change seemed not to work in the tamoxifen group.
Furthermore, the multivariable Cox proportional hazard.
ol n Z 140 Tamoxifen n Z 266 p
 12.0 29.5  20.3 0.007*
 12.8 28.2  27.2 0.056
 0.13 0.80  0.14 0.103
 1.2 5.6  2.9 0.175
 71.3 147.6  169.9 0.022*
 38.9 187.6  35.8 <0 .001*
 14.0 51.7  12.5 0.479
 31.3 92.3  27.9 <0.001*
 21.4 99.3  18.0 0.753
 8.3 5.9  2.9 0.312
 9.3 7.8  7.8 0.540
 2.53 1.97  2.02 0.564
t p < 0.05.
1C Z hemoglobin A1c; HDL Z high-density lipoprotein; HOMAR-
low-density lipoprotein; TG Z triglyceride; UA Z uric acid.
Table 3 The relationships of five categories of fatty liver change and the percentage of abnormal liver function test (LFT)
between two groups of breast cancer patients at follow-up time.
Abnormal LFT AST 35 ALT 40
Ultrasound Control n Z 8
(5.7%)
Tamoxifen n Z 45
(16.9%)
Control n Z 15
(10.7%)
Tamoxifen n Z 46
(17.3%)
(1) Fatty improved n Z 28 1/17 (5.9%) 0/11 (0) 2/17 (11.8%) 0/11 (0)
(2) Normal no change n Z 173 1/80 (1.3%) 1/93 (1.1%) 2/80 (2.6%) 1/93 (1.1%)
(3) Fatty no change n Z 66 5/27 (18.5%) 9/39 (23.1%) 6/27 (22.2%) 8/39 (20.5%)
(4) Normal to fatty n Z 72 1/7 (14.3%) 11/65 (16.9%) 3/7 (42.9%) 14/65 (21.5%)
(5) Worsened fatty n Z 67 0/9 (0) 24/58 (41.4%) 2/9 (22.2%) 23/58 (39.7%)
p for c2 test <0.001 <0.001
ALT Z alanine transaminase; AST Z aspartate aminotransferase.
416 H.-J. Pan et al.regression model adjusted for the above factors showed that
tamoxifen use had a significant influence, as our study
showed that not only “newly developed” fatty liver increased
but also “improved” fatty liver was impeded, and it even led
to a greater risk of “ worsened” fatty liver.
Several drugs can induce variable extents of fatty liver, so
to assess drug-related fatty liver we also considered the po-
tential effect of chemotherapy.22 To discuss the confounding
effect of chemotherapy, we noticed the chemotherapy rate
was lower in the tamoxifen group than the control group
(47.4% vs. 72.1%); this negative association implied that
chemotherapy did not influence the development of fatty
liver in our study. However, to clarify the influence of
chemotherapy, we adjusted it in themultivariate analysis and
still found a significant effect of tamoxifen treatment on
different conditions of NAFLD among breast cancer patients.
The precise mechanisms of drug-induced liver injury are not
always known, it is thought that they are mostly related to
mitochondrial dysfunction and can lead to hepatic cytolysis
and steatosis.23 The current hypothesis suggests that tamox-
ifen causes fatty liver via promoting de novo fatty acid syn-
thesis and inhibiting fatty acid b-oxidation.22,24 From
laboratory results, relatively higher triglyceride levels were
found in the tamoxifen group, and this may explain how the
drug exerts its effect through the interference of the triglyc-
eride metabolic pathway. Interestingly, the tamoxifen group
had relatively lower total cholesterol (205.6 38.9 mg/dL vs.
187.6 35.8 mg/dL, p< 0.001) and LDL (107.3  31.3 mg/dL
vs. 92.3 27.9mg/dL,p< 0.001), and some studies have even
demonstrated that tamoxifen is beneficial for the cardiovas-
cular system.25 This topic is beyond the scope of the currentTable 4 The effect of tamoxifen treatment on different
conditions of nonalcoholic fatty liver disease among breast
cancer patients.
HR (95% CI) p*
Newly developed fatty liver 3.69 (1.678.13) <0.001
Improved fatty liver 0.33 (0.150.75) 0.002
Worsened fatty liver 2.11 (1.024.35) <0.001
Multivariate analysis was adjusted with age, initial BMI, dia-
betes, chemotherapy, and exercise time >150 min/wk.
*Cox proportional hazard regression analysis. BMI Z body mass
index; CI Z confidence interval.study and additional research is needed to investigate the
potential cardiovascular benefits of tamoxifen.
The relationship of NAFLD and LFT
In the general population, NAFLD is recognized as the most
common cause of abnormal LFT. In a recent study with 1118
adults in the UK, abnormal LFT was identified in 55% of
patients and NAFLD in 26.4% of patients,26 in contrast, we
could not determine what percentage of abnormal LFT
would be found in NAFLD. Abdominal ultrasound is aimed at
detecting early liver metastasis in routine breast cancer
follow-up studies; hence, we wished to have a reference
concerning the rate of abnormal LFT under the relevant
abdominal ultrasound diagnosed fatty liver. In our study, we
determined that the consequent prevalence of abnormal
LFT increased in accordance with the severity of fatty liver.
For example, if a patient has a moderate fatty liver con-
dition, they might have an approximately 30% possibility of
abnormal LFT. The clinical implication is that physicians
may have an idea about the possibility of abnormal LFT
once the patient develops fatty liver.
Strengths
Many papers have documented the effect of tamoxifen-
induced fatty liver; however, few have discussed the
impact on the underlying fatty liver condition and lack
consideration for personal health conditions. In our study,
participants with varying extents of fatty liver were
enrolled and three different aspects were used to assess
the effect of tamoxifen. We also adjusted for personal
lifestyle and initial body weight to clarify the drug effect.
The positive relationships between fatty liver and abnormal
LFT can offer clinical physicians a reference for evaluation.
Limitations
Firstly, the sensitivity and specificity of abdominal ultra-
sound are not as accurate as liver biopsy, and interobserver
agreement is problematic.27 Abdominal ultrasound is a
simple, noninvasive, and inexpensive instrument to detect
fatty liver. It offers a reliable and accurate detection of
moderate to severe fatty liver28 and raters are unaware of
the patient’s background, hence, it has nondifferential
Tamoxifen-related fatty liver 417misclassification and should not influence the result. Sec-
ondly, for baseline characteristics, we only had the data of
body weight and AST; ALT, and other metabolic results were
not available, so we are unable to differentiate such
metabolic abnormalities in the tamoxifen group occurring
previously or afterwards.Conclusion
Our study suggests that tamoxifen is associated with the risk
of NAFLD development, either by increasing the developed
fatty liver or worsening the previous fatty liver condition and
even retarding fatty liver improvement. The severity of fatty
liver is associated with higher rates of abnormal LFT. During
the follow-up period, regular abdominal ultrasound
checkup, not just for detecting liver nodules, but also for
identifying fatty liver change, is crucial. Further checking of
liver function and other metabolic conditions once the fatty
liver condition has progressed is essential.Acknowledgments
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